Geode Capital Management, LLC Monopar Therapeutics Transaction History

Geode Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$0.59 - $0.94 $11,113 - $17,706	18,837 Added 45.72%	60,036 $43,000
Q3 2023 Nov 13, 2023	SELL	$0.57 - $1.0 $395 - $693	-693 Reduced 1.65%	41,199 $25,000
Q4 2022 Feb 13, 2023	BUY	$2.05 - $14.95 $5,578 - $40,678	2,721 Added 6.95%	41,892 $99,000
Q3 2021 Nov 12, 2021	BUY	$4.5 - $6.0 $46,845 - $62,460	10,410 Added 36.19%	39,171 $189,000
Q2 2021 Aug 13, 2021	BUY	$5.05 - $6.49 $11,953 - $15,361	2,367 Added 8.97%	28,761 $169,000
Q1 2021 May 12, 2021	BUY	$5.76 - $10.6 $152,029 - $279,776	26,394 New	26,394 $163,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $316M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.